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Abstract
Background: Past meta-analyses have shown adjunctive systemic Azithromycin (AZI) to provide minor clinical
benefits in scaling and root surface debridement (S/RSD). However, these have not considered the covariance of
key outcome parameters; probing pocket depth (PPD) and Clinical Attachment Level (CAL) or systematically
examined some potential sources of heterogeneity.
Aim: To jointly synthesize 6-month outcomes of systemic AZI as adjunctive to S/RSD in chronic periodontitis and
investigate 3 potential sources of heterogeneity.
Methods: Four databases were searched for suitable randomized controlled clinical trials (RCTs). Standardized mean
differences (SMD) in PPD and CAL between AZI + S/RSD and S/RSD alone, at 6-month follow-up were computed.
Within-study covariances of PPD and CAL were derived from reported multiple time-point data. A multivariate
meta-analysis with random effects jointly modelled PPD and CAL, factoring in their covariance. This model included
3 moderators with interaction effects; timing of AZI initiation (pre-therapy/post-therapy), type of S/RSD [full-mouth
debridement (FMD)/partial-mouth debridement (PMD)], and baseline study-level mean values of PPD/CAL.
Results: Among 276 abstracts, 11 observations from 9 RCTs qualified for meta-analysis. Within-study correlation-
coefficients of PPD with CAL significantly increased with increasing study-level baseline mean values (Spearman’s r = 0.79,
p < 0.01). The full multivariate meta-analysis model showed significant effects for the 3 moderators (Q statistic = 150.03,
p < 0.01), retained significant residual heterogeneity (Q statistic = 88.50, p < 0.01) but outperformed (Likelihood- ratio
statistic = 102.95, p < 0.01,) a null-model with no moderators (Q statistic = 201.5, p < 0.01). A significant effect was
seen only on the SMD for PPD (estimate = 1.16 mm, 95% CI: 0.27 mm–2.07 mmmm, p = 0.01) but not CAL
(estimate = 0.17 mm, 95% CI: -0.92 mm-1.26 mm, p = 0.76). SMD in PPD positively interacted with study baseline
value (estimate = 0.11, 95% CI: 0.08–0.15, p < 0.01). Significant negative interactions of SMD in PPD with PMD
(estimate = − 1.25mm, 95% CI: -1.73 mm- -0.78 mm, p < 0.01) and pre-therapy drug initiation (estimate = − 1.18mm,
95% CI: -1.48 mm--0.87 mm, p < 0.01) were evident.
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Conclusion: Joint synthesis of PPD and CAL showed, at 6-months, AZI + S/RSD provided a benefit over S/RSD alone
for PPD alone when correlation with CAL was accounted for. Deeper study-level baseline PPD, FMD type of S/RSD, and
post-therapy drug initiation associated with greater PPD reduction.
Keywords: Azithromycin, Periodontitis, Non-surgical periodontal therapy, Meta-analysis
Introduction
Clinical benefits of antibiotics as adjuncts to scaling and
root surface debridement (S/RSD) are recognized, although
overall small in magnitude [1–3]. Factors that could explain
heterogeneous outcomes in this regard are not systematic-
ally examined. An understanding of such factors is critical
to enable selection of the right patient, where the clinical
benefit of adjunctive antibiotics outweighs risks of anti-
microbial resistance, a key issue concerning antimicrobial
use. Furthermore, as initial benefits of antibiotics as ad-
juncts to S/RSD may not be sustained after a single course
[4, 5], there is a need for evidence synthesis at long
post-therapeutic periods. Among antimicrobial agents, Azi-
thromycin (AZI) is concentrated in fibroblasts, phagocytes,
[6] and gingival tissues [7] and possesses anti-inflammatory,
immunomodulatory characteristics [8]. As compared to the
most documented adjunctive antimicrobial regimen of
Amoxicillin and Metronidazole, systemic AZI entails higher
patient compliance, a longer therapeutic window, and fewer
side effects [9, 10]. Four previous systematic reviews have
summarised the evidence regarding AZI as an adjunct to S/
RSD [11–14]. Two reviews did not perform meta-analyses,
citing high trial heterogeneity [11, 12]. The two existing
meta-analyses have analyzed changes in probing pocket
depth (PPD) and clinical attachment level (CAL) in separ-
ate analyses [13, 14]. In clinical populations, these two out-
comes can be significantly correlated or inter-dependent.
The strength of such correlation, however, is shown to vary
widely, depending upon the disease severity [15]. As a re-
sult, the effect of different within-study correlations of these
two key outcomes can result in bias if ignored [16, 17]. A
multivariate meta-analysis can simultaneously analyze mul-
tiple correlated outcomes [18]. This approach has several
advantages over univariate approaches. It generates
improved estimates of effect sizes of correlated outcomes
and estimates their association, which may be useful for
prediction [16, 17]. Recognizing this fact, a multivariate
meta-analysis approach has been successfully applied to the
primary periodontal parameters PPD and CAL [19]. A
similar approach would be valuable to estimate the true
effects of systemic AZI as an adjunct to S/RSD.
Other aspects of data synthesis in the two existing
meta-analyses suggest directions for further research. One
meta-analysis summarised evidence from trials of both
systemic and local AZI in chronic or aggressive periodon-
titis [13], which could underpin variability in outcomes.
Here, the outcome measures were pooled estimates of
12improvements in clinical parameters in treatment and
control groups each. A large effect for each group was
noted. However, as there was no statistical comparison of
these effects a clear conclusion regarding their compara-
tive benefits remained unclear [13]. A second
meta-analysis that summarised evidence from randomized
clinical trials of adjunctive systemic AZI to S/RSD in
chronic periodontitis alone used raw mean differences in
clinical parameters between treatment and control group
as the outcome [14]. A limitation is that differences in
numbers of subjects per study is not accounted for in this
approach, and may be a source of bias. This study ana-
lyzed 2 potential sources of heterogeneity by subgroup
analyses; the severity of disease and the post-treatment ob-
servation time. Additional factors could drive variability in
the clinical outcomes of adjunctive AZI. S/RSD may be
delivered as a full-mouth debridement (FMD) instead of
the typical partial mouth debridement (PMD) regime such
as a quadrant-wise approach [20]. FMD may itself confer
additional treatment benefit [20, 21]. The timing of drug
initiation, either preceding biofilm removal or afterward,
varies across trials as there is no widely accepted standard
and may also impact outcomes [22]. The multivariate ap-
proach can jointly synthesize correlated outcomes while
describing the effects of potential moderators. In addition,
the between-study random variance may be estimated in
this advanced meta-analysis approach. Therefore, the
current study aimed to; i) jointly synthesize the benefits in
key periodontal outcomes (PPD and CAL) due to systemic
AZI as an adjunct to S/RSD and, ii) investigate 3 potential
moderating factors, by applying a multivariate meta-ana-
lysis approach.
Methods
A detailed protocol was designed based on the PRISMA
guidelines [23] and the study was conducted following
recommendations from the Cochrane Collaboration [24].
The study protocol was registered in the PROSPERO
database (PROSPERO 2018, ID = CRD42018093238).
Focused question
The focused question addressed in this study is “What is
the clinical benefit of systemic azithromycin as an adjunct
to scaling and root debridement in the treatment of
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chronic periodontitis as compared to scaling and root de-
bridement alone at 6 months post-therapy and how do 3
selected factors (timing of AZI initiation, type of S/RSD
and baseline study-level mean values of PPD/CAL) modify
its outcomes?”
Search methods
Pubmed (https://www.ncbi.nlm.nih.gov/pubmed/), Embase
(http://www.embase.com/home) and Cochrane library
(http://www.cochrane.org) were initially searched for papers
published up to February 2018, to answer the focused ques-
tion. A broad search strategy was employed to capture as
many relevant studies as possible. The following keywords
were used: “Azithromycin”, “Periodontitis”, “Periodontal
Diseases”, “Periodontal Treatment” and “Periodontal Ther-
apy”. MeSH terms were used when the search engine of the
database permitted. OpenGrey database was searched for
unpublished reports (http://www.opengrey.eu/). The search
strategy for Pubmed is presented in Additional file 1: Table
S1. A manual search included issues in the past 20 years of
the following journals: Journal of Periodontology, Journal of
Clinical Periodontology, Journal of Dental Research, Journal
of Dentistry and Journal of the American Dental Associ-
ation. The reference lists of articles eventually included
were also searched, to identify additional relevant studies
until no new applicable titles appeared (saturation).
Study selection
In the first phase, two blinded reviewers (AA and GP)
independently selected references based on titles and ab-
stracts. From within this initial selection, studies were
further admitted into the second phase where the
full-text analysis was conducted based on the following
predetermined inclusion criteria:
1. Randomized controlled clinical trial.
2. Patients diagnosed with Chronic Periodontitis.
3. Studies comparing S/RSD (defined as ‘scaling and
root planing’)+AZI versus S/RSD.
4. Studies conducted on systemically healthy adult
patients.
5. Follow-up of at least 6 months reporting data on
clinical parameters (CAL, PPD, BOP) at the 6-
month time-point.
6. Publication in English.
These included studies were then qualitatively assessed.
The next phase involved quantitative analysis. For this
purpose, studies that described changes in periodontal
outcomes and associated standard deviation (SD) (or data
used to calculate them) were included. Displayed data
which could not estimate these outcomes were excluded.
The agreement between reviewers was determined by the
κ statistics and any disagreements were resolved by dis-
cussion until a consensus was reached.
Assessment of risk of bias
The two independent reviewers evaluated the method-
ology of the included papers. (OYF and GP). Studies
were appraised based on the Cochrane Risk of Bias Tool
25 and the recommendations of the CONSORT state-
ment [25]. Seven domains were assessed and judged as
either at low, unclear or high risk of bias (1.Selection
Bias\2.Allocation Bias \3.Performance Bias \4.Detection
Bias \5.Attrition Bias \6.Reporting Bias \7.Inclusion/Ex-
clusion Criteria.) A low risk of bias (L) was assigned
when all these criteria were met. When one or two of
the criteria were not met a moderate risk of bias (M)
was assigned and when 3 or more were violated, a high
risk of bias (H) was considered. Furthermore, a sum-
mary assessment of the risk of bias of all outcomes
across domains and across studies was conducted.
Outcome measures
The primary outcome measured changes in Probing Pocket
Depth (PPD) and Clinical Attachment Levels (CAL).
Data extraction and management
Data were collected by the primary reviewer (AA) and
systematically inserted into a table, using Microsoft
Excel. Duplicate data extraction was done by the second
reviewer (NJ) and the results were merged. Data on
demographic characteristics, study design, intervention
methodology and dosage, periodontal maintenance, fol-
low up period and adverse effects were extracted from
included studies. Numerical data was extracted from the
presented tables and standard errors were converted to
standard deviation (SD). Extracted data were
cross-checked three times and any disagreements were
resolved by discussion.
Statistical analysis
The data extracted from the selected studies were en-
tered manually into a database. Mean values, standard
deviations, and numbers of treated subjects in test and
control groups were extracted. If no standard deviation
was available then it was calculated based on standard
error and sample size, in accordance with the Cochrane
Handbook for Systematic Review of interventions and
used as the outcome measure in the meta-analysis.
Within-study correlation measures of PPD and CAL
were estimated from the summary statistics of the re-
peated PPD and CAL measures reported for multiple
times points (3–6 time points were reported per study).
These correlation values were then used to compute co-
variance and generate a variance-covariance matrix. The
final meta-analysis model was fit using standardized
Jagannathan et al. BMC Oral Health           (2019) 19:65 Page 3 of 16
mean difference (SMD) as the effect size [26] using a re-
stricted maximal likelihood (REML) estimator, using the
R package ‘metafor’ with the function ‘rma.mv’ (https://
cran.r-project.org/web/packages/metafor/). The study
was used as a random variance component. The full
model included 3 moderators; timing of drug, type of S/
RSD, and Baseline study mean value of outcomes (CAL,
PPD). The interactions of each with the outcome variables
were modeled. Model heterogeneity was assessed by the
Q statistic and test and an omnibus test assessed moder-
ator significance. A reduced model without any modera-
tors but only the study-level random variable was also
computed and the full model and the reduced model were
compared using log-likelihood ratio tests (LRT) and
funnel plots for visualization of heterogeneity.
Results
Study selection
The electronic and manual search yielded a total of 276
abstracts. During the first step of the study selection
process, 254 publications were excluded based on the
evaluation of titles and abstracts (κ = 0.9327). In the sec-
ond phase, complete full-texts of the remaining 22 studies
were thoroughly evaluated. A total of 13 articles were ex-
cluded in this phase because they did not fulfill the inclu-
sion criteria (κ =1.000) (Additional file 1: Table S2). The
remaining 9 articles were selected for qualitative analysis.
Nine of these were included in the meta-analysis for PPD
and CAL, and 8 were included for BOP. A flowchart of
the study selection process is shown in Fig. 1.
Quality assessment
Quality assessment of the 9 RCTs revealed that 4 studies
were at low risk of bias. Three studies were at high risk of
bias since they failed to detail the randomization process,
masking methodology, and sample size calculation which
estimates the minimum number of participants required to
detect a difference among the groups [25, 27, 28]. A sum-
mary of the quality assessment is presented in Fig. 2. High
risk of selection bias was reported in 11% of the included
trials due to non-random approaches in categorizing the
participants. Allocation bias was observed in 55.5% of the
trials due to inadequate concealment of the enrolling par-
ticipants. Performance Bias was reported in 22% of the in-
cluded trials as the participants and investigator were
incompletely blinded during the study.
Fig. 1 PRISMA flowchart showing the selection of studies
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Fig. 2 Summary of quality assessment of included studies
Jagannathan et al. BMC Oral Health           (2019) 19:65 Page 5 of 16
Summary of studies (based on the PICO guideline):
population
Clinical trials comprised a total of 393 participants with
211 males, with a minimum of 28 to a maximum of 164
patients with mean age spanning from 32 to 51. The
study centers were from a varied population of different
ethnic backgrounds. Table 1 summarizes the main char-
acteristics of the included studies.
Intervention/comparison
Periodontitis was evaluated by charting up to 6 sites per
tooth in all included studies. Follow-up periods varied
from 6 to 12months. Multiple time points (1–12months)
were reported for all 9 studies (Table 1), which enabled
the estimation of study-level correlation between the PPD
and CAL values. The time for prescription of AZI and the
S/RSD approaches were variable. FMD in a single sitting
was employed in 1 study [25], while 2 studies had sub-
groups which employed the use of both FMD and PMD
performed over 3–4 sessions [27, 29]. The remaining six
trials utilized a PMD approach with quadrant or
sextant-wise S/RSD performed in 3–4 sessions at an aver-
age of 5–7 days interval [28, 30–34]. Regarding the pre-
scription of AZI, 1 study administered 500mg for 5 days
[34]. Another study administered a 500mg loading dose
followed by 250mg once daily from days 2 to 5 [28], while
all other 7 studies used 500mg once daily for 3 days. How-
ever, the time of drug initiation was variable. There were 5
studies which started the drug regime on the last day of
treatment, whereas two studies started AZI, on the first
day of treatment (Table 1). Both studies on Japanese co-
horts initiated the drug prescription scheme 3 days prior
to non-surgical treatment [25, 27]. In one study AZI was
compared to other antibiotics, with the control group hav-
ing only S/RSD [34]. Another trial compared the use of
AZI and CHX mouth rinse each used as an adjunct to
FMD type of S/RSD and to PMD type S/RSD performed
quadrant-wise, with the control groups having S/RSD
alone [29]. CHX treated groups were not considered in
the present analysis.
Outcomes; probing depths and clinical attachment levels
Study outcomes are summarized in Table 2. Seven stud-
ies documented an advantageous effect of systemically
administered AZI compared to S/RSD alone with
regards to PPD reduction. Significantly higher PPD
change between 6 and 12 months for AZI adjunctive to
S/RSD was reported in 3 studies, [27, 30, 32]. Four stud-
ies showed a beneficial effect of systemic AZI compared
to S/RSD alone with regards to CAL gain [27, 30–32].
Compliance and adverse events
The majority of the studies analyzed compliance by
counting the number of tablets provided by the patient.
One paper did not report on the outcome of compliance
[30] whereas one study reported of a non-compliant par-
ticipant [28]. Adverse event reporting included diarrhea,
reported in 4 studies, which involved 5 subjects (Table
1). One study reported a case of an allergic reaction and
also difficulty in swallowing [32]. Another study had
subjects complaining of excessive sleepiness and dizzi-
ness [34]. Three trials reported no adverse events [29,
31, 33] while one did not document them [30].
Meta-analyses of primary outcomes
The meta-analysis was performed for 11 observations from
the 9 studies and results are summarized in Table 3. A sig-
nificant correlation of CAL versus PPD correlation coeffi-
cients (range: 0.18–0.73) and their study Baseline mean
values (range: 2.2mm – 6.7mm for PPD and 2.5–7.7mm
for CAL) was noted (Fig. 3) indicating that CAL and PPD
co-vary increasingly as their values increase (Spearman’s
correlation cofficient = 0.79, p < 0.01). The model perform-
ance was satisfactory (Table 3). The full-model’s profile
likelihood plot of the study-level random variance compo-
nent peaked at the parameter estimate (0.103) (Fig. 4a) and
predicted versus actual SMD values showed a linear rela-
tionship (Fig. 4b), reflecting acceptable model perform-
ance. Funnel plots (Fig. 5) showed the reduced model had
higher heterogeneity for SMD than the full model, for
which the plot closely approximated symmetry. The full
model was significantly different and had lower AIC (94.2
versus 185.2) compared to the reduced model (LRT =
102.94 p < 0.01). A forest plot of the full-model is shown in
Fig. 6, compared to a forest plot of the no moderators
model. In the full model, a significant effect was seen for
only on the SMD for PPD (estimated SMD= 1.16, 95% CI:
0.27–2.07, p = 0.01). Significant positive interaction was
noted for PPD with mean Baseline value (estimated SMD
= 0.11, 95% CI: 0.08–0.15) and negative interaction was
seen for PPD with PMD (estimated SMD= -1.25, 95% CI
= − 1.73- -0.78) and pre-therapy drug initiation (estimated
SMD= -1.18, 95% CI = − 1.48- -0.87) (Fig. 7) (Table 3).
Discussion
The current study applied a multivariate approach to
jointly synthesize PPD and CAL outcomes in AZI + S/RSD
as compared to S/RSD alone in the treatment of chronic
periodontitis [15]. Despite high concordance of the in-
cluded literature with the two previous meta-analyses [13,
14], this approach was distinctive in accommodating vary-
ing within-study correlations of the main outcome param-
eters and exploring possible sources of variability within a
single synthesis. As such, its main purpose was to attempt
some resolution of the previously noted heterogeneity in
clinical outcomes. The major finding was that when PPD
and CAL were modeled together factoring in their
within-study correlations and between-study variation was
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Table 2 Major clinical outcomes of included studies
Author/Year Clinical Attachment Level Probing depth
Mascarenhas
et al. 2005
[28]
Baseline Study Mean: 3.87 mm
CAL gain in shallow pocket, 6 month: Control - 0.11 mm; AZI -
0.55
mm (p < 0.05)
CAL gain in moderate pockets, 6 month: Control − 1.52 mm (p <
0.05); AZI − 1.01 mm (p < 0.05).
CAL gain in deep pockets, 6 months: Control - 1.32 mm (p < 0.05);
AZI - 2.56 mm (p < 0.05), Between group difference: p < 0.05
Baseline Study Mean: 4.47 mm
PPD reduction in shallow pocket, 6 month: Control: 0.02 mm; AZI:
0.43 mm (p < 0.05),
PPD reduction in moderate pocket,, 6 month: Control: 1.0 mm (p
< 0.05); AZI: 1.7 mm(p < 0.05). Between group difference: p < 0.05
PPD reduction in deep pocket,, 6 month: Control: 1.98 mm (p <
0.05); AZI: 3.52 mm (p < 0.05), Between group difference: p < 0.05
Gomi et al.
2007 [25]
Baseline Study Mean: 7.73 mm
Control: Baseline: 7.21 ± 1.37 mm; 25 weeks: 5.74 ± 0.96 mm
AZI: Baseline: 7.47 ± 1.96 mm; 25 weeks: 4.85 ± 1.05 mm.
Between group difference: P > 0.05 at 13 and 25 weeks
Baseline Study Mean: 4.11 mm
Control group: Baseline: 4.05 ± 0.68 mm; 25 weeks: 3.30 ± 0.36 mm
AZI: Baseline: 3.98 ± 1.06 mm; 25 weeks: 2.36 ± 0.76 mm
Between group difference: P < 0.001 at 13 and 25 weeks
Haffajee et al.
2007 [32]
Baseline Study Mean: 3.2 mm
CAL gain: 6 months- Control:0.12 ± 0.15, AZI: 0.17 ± 0.12 (p < 0.05)
Baseline Study Mean: 3.01 mm
PPD reduction: 6 months- Control: 0.45 ± 0.15 (p < 0.05), AZI: 0.103
± 0.11 (p < 0.0001)
Yashima et
al. 2009 [27]
(FMD)
Baseline Study Mean: 3.99 mm
Between FMD test control group difference: P < 0.01 at 1, 3, 6
months and P < 0.05 at 9 and 12 months
Between PMD test control group difference: P < 0.01 at 1 month,
P < 0.05 at 6, 9 and 12 months
Baseline Study Mean: 5.08 mm
Between FMD test and control groups: P < 0.05 at 6, 9 and 12
months
Between PMD test and control groups: P < 0.05 at 6, 9 and 12
months
Oteo et al.
2010 [30]
Baseline Study Mean: 3.51 mm
CAL gain: 6 months- Control:0.29 mm(P > 0.05), AZI:0.76 mm(P =
0.004)
Between group difference: P = 0.016 at 6 months
Baseline Study Mean: 2.92 mm
PPD reduction: 6 month-Control: 0.34 mm (p < 0.05), AZI: 0.8 mm
(p < 0.05)
Between group difference: P = 0.009
Sampaio et
al. 2011 [34]
Baseline Study Mean: 5.63 mm
CAL gain at 1 year: Control: 2.35 ± 1.70, AZI: 2.68 ± 1.76,
Between group difference P > 0.05
Baseline Study Mean: 4.92 mm
PPD reduction at 1 year: Control: 3.83 ± 1.92, AZI: 3.45 ± 1.74
Between group difference P > 0.05
Han et al.
2012 [33]
Baseline Study Mean: 5.5 mm
CAL gain in shallow pockets:
1 month-Control: 1.36 ± 0.5 mm; AZI: 1.47 ± 0.3 mm, 3 months-
Control: 1.48 ± 0.6, AZI: 1.58 ± 0.4 mm, 6 months- Control:1.54 ±
0.5 mm, AZI: 1.55 ± 0.5 mm.
CAL gain in moderate pockets:
1 month- Control: 0.33 ± 0.2 mm, AZI: 0.34 ± 0.2 mm, 3 months-
Control: 0.31 ± 0.2 mm, AZI: 0.43 ± 0.3 mm 6months-Control: 0.39
± 0.4 mm, AZI: 0.34 ± 0.2 mm.
CAL gain in deep pockets:
1 month- Control: 1.15 ± 2.3 mm; AZI: 1.99 ± 3.0 mm, 3 months-
Control: 0.49 ± 0.7 mm, AZI: 1.25 ± 1.9 mm 6months-Control: 0.54
± 0.5 mm, AZI: 2.25 ± 3.1 mm.
Oveall: P < 0.05 for Control and AZI both
Baseline Study Mean: 3.93 mm
PPD reduction in shallow pockets:
1 month-Control: 1.44 ± 0.5 mm; AZI: 1.56 ± 0.4 mm, 3 months-
Control: 1.54 ± 0.4 mm, AZI: 1.79 ± 0.4 mm, 6 months- Control: 4.45
± 0.5 mm, AZI: 1.81 ± 0.5 mm
PPD reduction in moderate pockets:
1 month- Control: 2.28 ± 0.3 mm, AZI: 2.18 ± 0.2 mm, 3 months-
Control: 2.30 ± 0.3 mm, AZI: 2.23 ± 0.3 mm, 6 months-Control: 2.46
± 0.3 mm, AZI: 2.32 ± 0.4 mm
PPD reduction in deep pockets:
1 month- Control: 4.11 ± 0.5 mm, AZI: 4.34 ± 0.9 mm, 3 months-
Control: 4.16 ± 0.4 mm, AZI: 4.46 ± 0.8 mm, 6 months-Control: 0.39
± 0.4 mm, AZI: 4.88 ± 1.1 mm
Overall: P < 0.05 for Control and AZI both
Fonseca et
al. 2015 [29]
FMD
Control: Baseline 2.39 ± 0.99 mm. 3 month: 2.17 ± 0.77 mm, 6
month 2.20 ± 0.74 mm at 180 days
AZI: Baseline 2.73 ± 1.15 mm, 3 month: 2.68 ± 1.14 mm, 6 month-
2.61 ± 1.15 mm
PMD
Control: Baseline: 2.6 ± 1.19 mm. 3 month: 2.46 ± 1.11 mm, 6
month-2.41 ± 1.04 mm
AZI: Baseline: 2.38 ± 0.79 mm, 3 month: 2.27 ± 0.71 mm, 6 month-
2.25 ± 0.72 mm
P < 0.05 at 3 months for control and AZI
FMD
Control group: Baseline 2.27 ± 0.60 mm, 3 month- 2.09 ± 0.52 mm,
6 month- 2.08 ± 0.52 mm
AZI: Baseline 2.20 ± 0.41 mm, 3 month- 2.11 ± 0.41 mm, 6 month-
1.93 ± 0.42 mm
PMD
Control: Baseline: 2.20 ± 0.55 mm, 3 month: 1.98 ± 0.54 mm, 6
month:1.93 ± 0.47 mm
AZI: Baseline: 2.31 ± 0.4 mm, 3 month- 2.21 ± 0.40 mm, 6 month-
2.18 ± 0.40 mm
Martande et
al. 2016 [31]
Baseline Study Mean: 7.76 mm
Control group: Baseline 7.63 ± 1.42 mm; 1 month- 6.80 ± 1.32, 3
month − 6.40 ± 1.06 mm, 6 month 6.06 ± 1.11 mm, 12 month-5.91
± 1.09 mm
AZI: Baseline 7.69 ± 1.02 mm; 1 month- 6.69 ± 1.17, 3 month- 5.54
± 0.89 mm, 6 month- 5.16 ± 1.10 mm, 12 month- 4.97 ± 1.18 mm
Between group difference: 3 months (P < 0.0005), 6 months (P =
0.0013), 12 months (P = 0.0009).
Baseline Study Mean: 6.66 mm
Control group; Baseline 6.74 ± 1.40 mm; 1 month- 6.00 ± 1.29, 3
month- 5.57 ± 1.17 mm, 6 month- 5.43 ± 1.24 mm, 12 month- 5.23
± 0.73 mm.
AZI: Baseline 6.57 ± 0.85 mm; 1 month- 5.29 ± 1.05, 3 month- 4.46
± 0.92 mm, 6 month- 3.74 ± 0.78 mm, 12month-3.66 ± 0.73 mm.
Between group difference: 1 month (P = 0.0024), 3 months (P <
0.0001), 6 months (P < 0.0001), and 12 months (P < 0.0001)
AZI Test group: Azithromycin + S/ RSD Group. C Control Group; SRSD alone, FMD Full mouth debridement, PMD Partial Mouth S/RSD,
(studies are ordered by year of publication)
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accounted for as a random variable, a significant effect of
AZI + S/RSD was noted only for PPD. This was a major
differentiating point from the results of the two past
meta-analysis [13, 14]. Multiple correlated outcome mea-
sures, such as key clinical periodontal measures, present a
particular challenge in synthesis. As noted previously [15],
we found the correlation of PPD and CAL increased with
increasing baseline values of these parameters (Fig. 3),
which suggested this relationship would significantly im-
pact the outcomes. A multivariate approach resolves this
issue by joint synthesis of these outcomes by accounting
for the covariance. It has been shown as a valuable
approach in synthesizing treatment outcomes of periodon-
tal disease [19], however, not widely applied. The major
Table 3 Results of the multivariate meta-analysis
Interacrtions in the full model = Outcome*Baseline Value, Outcome*S/RSD Type, Outcome*Timing
Parameter Estimated SMD P value 95% C.I
Outcome: CAL 0.17 0.76 -0.92-1.26
Outcome: PPD 1.17 0.01 0.27–2.07*
Baseline Value 0.01 0.87 −0.10-0.12
S/RSD Type: PMD (reference value = FMD) 0.22 0.50 −0.42-0.86
Timing: Pre-therapy (reference value = Post-Therapy) 0.13 0.72 −0.57-0.83
PPD*Baseline 0.11 < 0.01 0.08–0.15***
PPD*S/RSD Type PMD −1.25 < 0.01 −1.73--0.78***
PPD*Timing: Pre-therapy −1.18 < 0.01 −1.48--0.87***
Model Statistics
Log Likelihood ratio Deviance AIC BIC
−38.06 76.13 94.20 99.88
Variance Components: Study, number of levels = 09, Estimated 2 value: 0.10
Test for Residual Heterogeneity, Moderators and Model Comparison
Test for Residual Heterogeneity: QE (df = 14) = 88.50, p-value < 0.01
Test of Moderators: QM (df = 8) = 150.03, p-value < 0.01
Model comparsion with null model without moderators (ANOVA)
AIC Log Likelihood ratio Likelihood Ratio Test Statistic P value Model QE
Full model (df = 9) 94.20 −38.06 88.50
Reduced (df = 3) 185.23 −89.54 103.10 < 0.01 201.50
*p < 0.05, **p < 0.01, *** p < 0.0001, Significant values in bold font
Fig. 3 Within-study correlation of primary outcomes (Spearman’s r-value; PPD and CAL, y-axis) plotted against study-level Baseline Mean Values (blue: CAL,
red: PPD, x-axis). The size of the circle corresponds to the number of subjects in the study
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diagnostic criterion for chronic periodontitis has been the
presence of clinical attachment loss. As a result, study pop-
ulations may be expected to vary in probing pocket depth
distribution, as varying amounts of clinical attachment loss
may present as recession. In agreement, the study mean
values for these outcomes ranged 2.2mm – 6.7mm for
PPD and 2.5–7.7mm for CAL (Table 1), reflecting a wide
range of clinical disease severities and within-study correla-
tions of PPD and CAL (Spearman’s r = 0.19–0.73).
Notably, the confidence interval for the summary PPD
outcome was very large (0.27–2.06 mm) again suggesting
the actual clinical benefit is variable, possibly depending
on background factors. Two issues are relevant to this
finding. Firstly, the clinical measurement of probing
depth and clinical attachment loss with manual probing
is inherently subject to measurement error. The magni-
tude of such error has classically been reported as 0.36
mm and 0.41 mm respectively [35]. Moreover, in
untreated periodontitis, where there is lower resistance
to probing and presence of bleeding and root surface
calculus, measurement variability in manual probing
may be relatively higher [36]. Taken together, it appears
that the 95% CI for SMD accorded to the benefit of ad-
junctive AZI overlaps with the documented range of
Fig. 4 Model performance: 4a: The profile likelihood plot showing study-level random variance component (Sigma squared) for the full-model and 4b: the
actual versus the predicted SMD values (blue: CAL, red: PPD, The size of the circle corresponds to the number of subjects in the study)
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clinical error in probing, which may be a source of po-
tential bias. A second issue is the translation of the add-
itional reduction in PPD due to adjunctive AZI to a
reduction in the need for future surgery. A previous syn-
thesis, which assessed the value of adjunctive Amoxicil-
lin and Metronidazole to S/RSD found that despite a
clinical benefit in PPD reduction at 3–6 months, no not-
able benefit in terms of a need for periodontal surgery,
as indicated by a PPD of 3mm or less, was evident [37].
These authors also noted high heterogeneity in the in-
cluded studies, similar to the present synthesis. While
we did not directly extrapolate the need for periodontal
surgery as an outcome, the large range of the 95% CI in
PPD reduction appears cautionary against a blanket
assumption of such benefit attributable to adjunctive
AZI in all chronic periodontitis-affected sites. This find-
ing also emphasizes the need to investigate the sources
of variability in clinical outcomes as these would point
Fig. 5 Funnel plots for outcomes for the full-model (left) showed lower asymmetry than the reduced model (right)
Fig. 6 Forest plot depicting the full-model and moderators. The observations are ordered according to Outcome (PPD, CAL) and decreasing
Baseline Study Mean Values
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to patient profiles who may stand to benefit from this
intervention.
Although significant residual heterogeneity remained in
the full model, the test for moderators was significant and
it explained the outcomes significantly better as compared
to a model without any moderators. The moderator inter-
action effects were addressed in a single synthesis, unlike
past meta-analysis [14]. Two of the 3 included moderators
(type of S/RSD and timing of drug) have not been ad-
dressed in the context of adjunctive AZI outcomes in S/
RSD. For every 1mm increase in Baseline PPD, the
estimated SMD for AZI + S/RSD increased significantly by
0.11mm. Thus, increasingly deeper pockets thus benefited
the most from adjunctive systemic AZI at 6-months
post-therapy, in agreement with a previous meta-analysis
[14]. We did not categorize the pockets into deep, moder-
ate, and shallow, as a uniform categorization across all the
included primary literature was lacking. Considering Base-
line study mean value as a moderator allowed to test its
impact as a continuous variable applicable to all the in-
cluded cases. Arguably, this approach provided for better
statistical robustness as compared to the analysis of a
Fig. 7 a) Bar plots depicting the Standardized mean difference (SMD) in Outcomes within categories of ‘type of S/RSD’ (vertical panels) and ‘timing of
drug’ (horizontal panels -top) and b) Line plot showing Standardized mean difference (SMD) variation (y-axis) with Baseline mean value of PPD and CAL
(x-axis) (bottom)
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subset of studies alone which grouped pockets based on
depth-cut offs. In theory, greater benefit in PPD reduction
of increasingly deeper sites may translate to the lower
need for surgical intervention or lower risk of disease pro-
gression when AZI + S/RSD is applied in deep probing
sites. However, a cut-off value of Baseline PPD where this
approach lowers the need for periodontal surgery or pre-
vents further loss of attachment is unclear. These ques-
tions should be addressed by well-designed clinical trials
focussed on these two particular outcomes, with stringent
inclusion criteria.
A PMD approach showed an estimated significantly
lower SMD in PPD by 1.25 mm over the FMD approach
and pre-therapy drug initiation resulted in an estimated
lower SMD 1.18 mm as compared to post-therapy drug
initiation. These effect sizes are comparable to the over-
all main effect for PPD (1.17 mm) but with smaller con-
fidence intervals (Table 3). The finding that FMD was
superior to PMD is largely in agreement with the
full-mouth disinfection concept, which advocates a con-
junctive application of an antimicrobial agent with
complete mechanical debridement [20]. An FMD ap-
proach to S/RSD itself has not shown a clearly increased
benefit [38]. Notably, we did not consider the number of
sittings and their intervals over which PMD was per-
formed. These were variable across studies and may be
relevant factors to consider when comparing PMD with
the FMD approach. The drug half-life for AZI is 7 days.
With this basis, Yashima et al. (2009) [27] hypothesized
that when PMD is delivered within this time-frame, clin-
ical benefits would be comparable to the FMD approach
as compared to the typical PMD delivery in a quadrant
wise approach provided over 2–4 weekly intervals, as
noted in 7 of the included studies. This typical approach
would result in the debridement of some areas being
performed after the effective concentration of the drug
declined to non-therapeutic levels, which may be re-
sponsible for a lower benefit.
Much less is known about any impact of the
time-point of drug initiation. From a biological stand-
point, the time of drug initiation may lead to a difference
in drug therapeutic concentrations achieved either be-
fore or after the disruption of the periodontitis-related
biofilm. Secondly, it may affect whether the drug is lo-
cally active in a state of greater gingival crevicular fluid
flow and pocket-epithelial disruption induced by mech-
anical instrumentation. Particularly, as AZI tends to se-
questrate in the gingival crevicular fluid (GCF) more
than in the serum [39] and peak GCF concentration oc-
curs at 36 h [40], it seems plausible that its pharmaco-
kinetics may be used to an advantage by an immediate
post-S/RSD drug regime. This would be particularly rele-
vant to the PMD approach when the sittings are widely
spaced. Initiation in conjunction with or earlier to S/
RSD would result in high drug concentrations where in-
tact subgingival biofilm still remains which may result in
a lower clinical benefit, as noted in pre-therapy initiation
in this study. In an FMD approach, it is conceivable that
starting the drug prior to or immediately after S/RSD
would not impact its efficacy much as drug half-life
would coincide with the post-debridement time-frame.
The potential interaction between drug timing and S/
RSD type was not examined as there were no cases
where an FMD approach was used with post-therapeutic
intervention.
Taken together, the multivariate approach resolved part
of the heterogeneity noted in clinical outcomes of adjunct-
ive AZI in S/RSD in the treatment of chronic periodontitis.
Study-level differences in drug timing, baseline disease se-
verity, and type of S/RSD appear to impact the degree of
reduction in PPD attributed to adjunctive AZI at 6months
after S/RSD. The positive study-level random variance
(sigma 2) component depicted the existence of between-
study heterogeneity. Persistent residual heterogeneity was
noted in the full-model suggesting many unexamined po-
tential moderators exist. Chief among these would be
smoking, which reduces healing response to S/RSD [41],
plaque control and supportive therapy, which are key de-
terminants of outcome of nonsurgical periodontal therapy
[42, 43]. Notably, the maintenance regimes followed by the
studies included varied considerably in terms of the time
interval. The major limitation of this synthesis was a small
number of qualifiable studies for analyses. Large-scale, stan-
dardized and well-designed RCTs are required to investi-
gate the moderators suggested by this analysis and facilitate
concrete recommendations. Clinical end-points in future
studies should include the proportion of remaining deep
pockets, sites that undergo progression, need for surgery,
and patient-related outcomes.
Conclusion
Adjunctive systemic AZI with S/RSD can confer signifi-
cant additional but variable clinical benefit in PPD reduc-
tion at 6months after therapy as compared to scaling and
root surface debridement alone. The magnitude of this
benefit is influenced by baseline disease severity, the tim-
ing of the drug initiation, and type of non-surgical therapy.
Single sitting full-mouth debridement and drug initiation
post-instrumentation have a beneficial interaction with
this intervention.
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